Researchers at the University of Bath are leading a new £500,000 research initiative using cutting-edge organ-on-a-chip technology to investigate how diabetes contributes to memory loss and cognitive decline.
The project, known as GlucoBrain, creates a miniature connectivity system that mimics the communication between the brain, gut, and pancreas.
The three-year study brought together scientists from the University of Bath, as well as the University of Oxford and Johns Hopkins University, to create what researchers say is the first multi-organ platform.
Organ-on-a-chip devices are designed to track how biological signals travel between organs and how blood sugar levels affect brain function.
Researchers believe this organ-on-a-chip model could provide important insights into why patients with diabetes appear to be at higher risk of developing dementia-related diseases, including Alzheimer’s disease.
This technology also has the potential to accelerate drug discovery and reduce reliance on animal testing by providing a more accurate human-based research system.
GlucoBrain is being funded through the Engineering and Physical Sciences Research Council’s (EPSRC) Health Technologies Connectivity Awards program and is scheduled to launch in October.
Organ-on-a-chip technology targets major medical mysteries
Diabetes and dementia remain two of the most significant health challenges facing aging populations around the world.
Diabetes is commonly associated with cardiovascular disease, kidney damage, and visual impairment, but increasing evidence suggests that it can also affect memory, learning, and overall cognitive performance.
Scientists have struggled to pinpoint the biological pathways involved in the relationship between diabetes and dementia.
Existing studies rely heavily on animal models, patient observations, and basic cell cultures and are often unable to reproduce the complex communication networks between human organs.
The GlucoBrain project aims to fill that gap using organ-on-a-chip technology. These miniature systems use living human cells housed in artificial devices that replicate the environment and function of real organs.
Unlike traditional Petri dish culture, organ-on-a-chip platforms allow cells to grow in three dimensions while receiving controlled nutrients and biochemical signals.
By connecting separate models of the intestine, pancreas, and brain, researchers will be able to monitor in real time how hormones, blood sugar fluctuations, and cellular signals affect each organ.
Multi-organ systems more closely replicate human biology
The project team plans to first build individual organ-on-a-chip models and then integrate them into a connected system that can simulate interactions throughout the body.
Researchers gradually increase the complexity of their models to observe how organs respond to changes in blood sugar levels or experimental drug treatments. This approach is expected to produce more physiologically accurate data than many current clinical testing methods.
Clinical experts at the University of Oxford support the development of diabetes and metabolic disease models to ensure the systems reflect real biological processes.
Meanwhile, researchers at Johns Hopkins University will offer their expertise in Alzheimer’s disease and brain organoids, small lab-grown tissue models that mimic aspects of the human brain.
This interdisciplinary program also includes engineers, biologists, clinicians, and computer scientists who collaborate to model disease progression and organ communication.
Organ-on-a-chip research could change drug development
Scientists involved in the project believe the organ-on-a-chip system has the potential to change the way researchers study chronic diseases and test potential treatments.
Because this technique uses human cells rather than animal models, it may yield results more relevant to human biology. Researchers also hope the platform will improve the speed and efficiency of drug testing, while reducing research costs in the long term.
The long-term goal is to combine organ-on-a-chip systems with artificial intelligence to better understand how diseases develop and interact throughout the body.
Researchers say future versions could ultimately support personalized medicine by using a patient’s own cells to predict which treatments will be most effective.
As organ-on-a-chip technology continues to evolve, projects like GlucoBrain are placing the field at the center of the next generation of medical research, especially in areas where multiple diseases intersect and traditional laboratory models have struggled to provide answers.
Source link
